Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers

[Display omitted] •TMZ is the first line drug in GBM treatment but has physical–chemical limitations.•GBM have been showing increasing resistance to TMZ treatment.•Alternative strategies have been developed to improve anticancer chemotherapy.•Drug delivery using nanocarriers can improve biological p...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmaceutics and biopharmaceutics 2021-11, Vol.168, p.76-89
Main Authors: Delello Di Filippo, Leonardo, Hofstätter Azambuja, Juliana, Paes Dutra, Jessyca Aparecida, Tavares Luiz, Marcela, Lobato Duarte, Jonatas, Nicoleti, Luiza Ribeiro, Olalla Saad, Sara Teresinha, Chorilli, Marlus
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents, Alkylating - administration & dosage
Antineoplastic Agents, Alkylating - adverse effects
Antineoplastic Agents, Alkylating - pharmacokinetics
Brain cancer
Brain Neoplasms - drug therapy
Cancer therapy
Drug Carriers - chemistry
Drug Delivery Systems
Drug resistance
Drug Resistance, Neoplasm
Functionalization
Glioblastoma
Glioblastoma - drug therapy
Humans
Nanoparticles
Nanotechnology
Temozolomide - administration & dosage
Temozolomide - adverse effects
Temozolomide - pharmacokinetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!